Catalyst Pharmaceuticals (Nasdaq:CPRX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CPRX 주식 개요

카탈리스트 파마슈티컬스는 상업화 단계의 바이오 제약 회사로, 미국에서 희귀 쇠약성, 만성 신경근육 및 신경 질환 환자를 위한 치료제를 개발하고 상용화하는 데 주력하고 있습니다.

CPRX 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	4/6
과거 실적	2/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 72.8% 에서 거래

수익은 매년 20% 증가할 것으로 예상됩니다.

분석가들은 주가가 82.3% 상승할 것이라는 데 동의합니다.

위험 분석

지난 1년 동안 주주가 희석되었습니다.

지난 3개월간 상당한 내부자 매도

이익 마진 (15.8%) 작년보다 낮습니다 (38.8%)

Catalyst Pharmaceuticals, Inc. 경쟁사

MannKind

NasdaqGM:MNKD

US$1.4b

Protagonist Therapeutics

NasdaqGM:PTGX

US$1.9b

Dynavax Technologies

NasdaqGS:DVAX

US$1.5b

Kiniksa Pharmaceuticals

NasdaqGS:KNSA

US$1.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Catalyst Pharmaceuticals
과거 주가
현재 주가	US$15.39
52주 최고치	US$17.50
52주 최저치	US$11.55
베타	0.73
11개월 변경	-3.02%
3개월 변경 사항	-2.29%
1년 변경 사항	19.30%
33년 변화	159.09%
5년 변화	288.64%
IPO 이후 변화	152.30%

최근 뉴스 및 업데이트

Recent updates

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

주주 수익률

	CPRX	US Biotechs	US 마켓
7D	2.6%	2.1%	-0.5%
1Y	19.3%	12.0%	24.2%

수익률 대 산업: CPRX 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: CPRX 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Average Weekly Movement	4.8%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: CPRX 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: CPRX 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2002	167	Rich Daly	www.catalystpharma.com

카탈리스트 파마슈티컬스는 상업화 단계의 바이오 제약 회사로, 미국에서 희귀 쇠약성, 만성 신경근육 및 신경 질환 환자를 위한 치료제를 개발하고 상업화하는 데 주력하고 있습니다. 램버트-이튼 근위축성 증후군(LEMS) 환자 치료를 위한 아미팜프리딘 인산염 정제인 퍼댑스와 소아 LEMS 환자 치료를 위한 루저기를 공급하고 있습니다. 이 회사는 MuSK 항체 양성 중증 근무력증 및 척수성 근위축증 치료를 위한 Firdapse를 개발하고 있습니다.

Catalyst Pharmaceuticals, Inc. 기본 사항 요약

Catalyst Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
CPRX 기본 통계
시가총액	US$1.84b
수익(TTM)	US$65.12m
수익(TTM)	US$411.35m

27.9x

P/E 비율

4.4x

P/S 비율

CPRX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
CPRX 손익 계산서(TTM)
수익	US$411.35m
수익 비용	US$146.71m
총 이익	US$264.64m
기타 비용	US$199.52m
수익	US$65.12m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.55
총 마진	64.33%
순이익 마진	15.83%
부채/자본 비율	0%

CPRX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

CPRX 주식 개요

보상

위험 분석

Catalyst Pharmaceuticals, Inc. 경쟁사

NasdaqGM:MNKD

US$1.4b

NasdaqGM:PTGX

US$1.9b

NasdaqGS:DVAX

US$1.5b

NasdaqGS:KNSA

US$1.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Recent updates

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment deteriorates as stock falls 30%

Investor sentiment improved over the past week

Chief Medical & Regulatory Officer exercised options and sold US$100k worth of stock

Chief Accounting Officer recently sold US$2.0m worth of stock

Independent Director recently sold US$332k worth of stock